|
KMID : 0620920230550071413
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 7 p.1413 ~ p.1423
|
|
|
Decorin: a potential therapeutic candidate for ligamentum flavum hypertrophy by antagonizing TGF-β1
|
|
Shanxi Wang
Yunkun Qu
Xuan Fang
Qing Ding
Hongqi Zhao
Xiaojun Yu
Tao Xu
Lee Ji-Young
Shaoze Jing
Chaoxu Liu
Hua Wu
Yang Liu
|
|
|
Abstract
|
|
|
|
Ligamentum flavum hypertrophy (LFH) is the main physiological and pathological mechanism of lumbar spinal canal stenosis (LSCS). The specific mechanism for LFH has not been completely clarified. In this study, bioinformatic analysis, human ligamentum flavum (LF) tissues collection and analysis, and in vitro and in vivo experiments were conducted to explore the effect of decorin (DCN) on LFH pathogenesis. Here, we found that TGF-β1, collagen I, collagen III, α-SMA and fibronectin were significantly upregulated in hypertrophic LF samples. The DCN protein expression in hypertrophic LF samples was higher than that in non-LFH samples, but the difference was not significant. DCN inhibited the expression of TGF-β1-induced fibrosis-associated proteins in human LF cells, including collagen I, collagen III, α-SMA, and fibronectin. ELISAs showed that TGF-β1 can upregulate PINP and PIIINP in the cell supernatant, and this effect was inhibited after DCN administration. Mechanistic studies revealed that DCN suppressed TGF-β1-induced fibrosis by blocking the TGF-β1/SMAD3 signaling pathway. In addition, DCN ameliorated mechanical stress-induced LFH in vivo. In summary, our findings indicated that DCN ameliorated mechanical stress-induced LFH by antagonizing the TGF-β1/SMAD3 signaling pathway in vitro and in vivo. These findings imply that DCN is a potential therapeutic candidate for ligamentum flavum hypertrophy.
|
|
|
KEYWORD
|
|
|
Neuromuscular disease, Transdifferentiation, Drug development, Ligaments, Molecularly targeted therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|